Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain.[1]
| Combination of | |
|---|---|
| Celecoxib | Nonsteroidal anti-inflammatory drug (NSAID) |
| Tramadol hydrochloride | Opioid agonist |
| Clinical data | |
| Trade names | Seglentis |
| Other names | E-58425 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021.[1][2][3]
References edit
- ^ a b c "Seglentis- celecoxib and tramadol hydrochloride tablet". DailyMed. Retrieved 8 January 2022.
- ^ "Seglentis: FDA-Approved Drugs". U.S. Food and Drug Administration. Retrieved 18 October 2021.
- ^ "Esteve Announces FDA Approval Of A Novel Co-Crystal Form Of Celecoxib And Tramadol For The Management Of Acute Pain". Esteve (Press release). 15 October 2021. Retrieved 18 October 2021.
External links edit
- "Celecoxib". Drug Information Portal. U.S. National Library of Medicine.
- "Tramadol hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03108482 for "Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial." at ClinicalTrials.gov
 | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |